Gastric Cancer Risk in Patients with Helicobacter pylori Infection and Following Its Eradication

Gastroenterology Clinics of North America

Volumn 44, Issue 3, 2015, Pages 609-624

  Rugge, Massimo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Atrophic gastritis; Gastric cancer prevention; Gastric cancer risk; H pylori; OLGA staging; Pepsinogens

Indexed keywords

GASTRIN 17; PEPSINOGEN; PEPSINOGEN I; PEPSINOGEN II; ANTIINFECTIVE AGENT;

BACTERIAL CLEARANCE; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOGENIC ACTIVITY; DISEASE SEVERITY; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; INTESTINE METAPLASIA; INVASIVE PROCEDURE; NON INVASIVE PROCEDURE; NONHUMAN; PREDICTIVE VALUE; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; STOMACH ATROPHY; STOMACH BIOPSY; STOMACH CANCER; COMPLICATION; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICROBIOLOGY; PATHOLOGY; STOMACH TUMOR;

ANTI-BACTERIAL AGENTS; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 84940451690     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2015.05.009     Document Type: Review

References (69)

1. Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014, 513:202-209.
2. Rugge M., Capelle L.G., Fassan M. Individual risk stratification of gastric cancer: evolving concepts and their impact on clinical practice. Best Pract Res Clin Gastroenterol 2014, 28:1043-1053.
3. Rugge M., Correa P., Dixon M.F., et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000, 24:167-176.
4. Correa P. Gastric cancer: overview. Gastroenterol Clin North Am 2013, 42:211-217.
5. Lochhead P., El-Omar E.M. Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol 2007, 2:281-297.
6. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
7. Ernst P.B., Gold B.D. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 2000, 54:615-640.
8. Malaty H.M. Epidemiology of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 2007, 21:205-214.
9. Wroblewski L.E., Peek R.M., Wilson K.T. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010, 23:713-739.
10. Zhang S., Desrosiers J., Aponte-Pieras J.R., et al. Human immune responses to H. pylori HLA class II epitopes identified by immunoinformatic methods. PLoS One 2014, 9:e94974.
11. Malfertheiner P., Megraud F., O'Morain C.A., European Helicobacter Study Group, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012, 61:646-664.
12. Graham D.Y. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 2015, 148(4):719-731.e3.
13. Kimko H., Thyssen A., Mould D.R., et al. Helicobacter pylori treatment in children: defining a dose for rabeprazole as a part of a triple therapy regimen. J Clin Pharmacol 2015, 55(5):592-600.
14. Zhu R., Chen K., Zheng Y.Y., et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol 2014, 20:18013-18021.
15. Sakakibara M., Ando T., Ishiguro K., et al. Usefulness of Helicobacter pylori eradication for precancerous lesions of the gastric remnant. Gastroenterol Hepatol 2014, 4:60-64.
16. Yoon H., Kim N. Diagnosis and management of high risk group for gastric cancer. Gut Liver 2015, 9:5-17.
17. Kelley J.R., Duggan J.M. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003, 56:1-9.
18. Sipponen P., Graham D.Y. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scand J Gastroenterol 2007, 42:2-10.
19. Di Mario F., Cavallaro L.G. Non-invasive tests in gastric diseases. Dig Liver Dis 2008, 40:523-530.
20. Väänänen H., Vauhkonen M., Helske T., et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Gastroenterol Hepatol 2003, 15:885-891.
21. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006, 9:245-253.
22. Iijima K., Abe Y., Kikuchi R., et al. Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol 2009, 15:853-859.
23. Rugge M., de Boni M., Pennelli G., et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010, 31:1104-1111.
24. Dinis-Ribeiro M., da Costa-Pereira A., Lopes C., et al. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia 2004, 6:449-456.
25. Tu H., Sun L., Dong X., et al. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study. Int J Cancer 2015, 136:425-434.
26. Correa P. Serum pepsinogens in gastric cancer screening. Dig Dis Sci 2010, 55:2123-2125.
27. Shiotani A., Cen P., Graham D.Y. Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol 2013, 23:492-501.
28. Dinis-Ribeiro M., Areia M., de Vries A.C., et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012, 44:74-94.
29. Leja M., Kupcinskas L., Funka K., et al. Value of gastrin-17 in detecting antral atrophy. Adv Med Sci 2011, 56:145-150.
30. McNicholl A.G., Forné M., Barrio J., et al. Accuracy of GastroPanel for the diagnosis of atrophic gastritis. Eur J Gastroenterol Hepatol 2014, 26(9):941-948.
31. Sugano K, Tack J, Kuipers EJ, et al. Kyoto Global Consensus Report on Helicobacter pylori gastritis. Gut, in press.
32. Gonen C., Simsek I., Sarioglu S., et al. Comparison of high resolution magnifying endoscopy and standard videoendoscopy for the diagnosis of Helicobacter pylori gastritis in routine clinical practice: a prospective study. Helicobacter 2009, 14:12-21.
33. Uedo N., Ishihara R., Iishi H., et al. Endoscopy. A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. Endoscopy 2006, 38:819-824.
34. Okubo M., Tahara T., Shibata T., et al. Usefulness of magnifying narrow-band imaging endoscopy in the Helicobacter pylori-related chronic gastritis. Digestion 2011, 83:161-166.
35. Rugge M., Pennelli G., Pilozzi E., et al. Gastritis: the histology report. Dig Liver Dis 2011, 43:S373-S384.
36. Dixon M.F., Genta R.M., Yardley J.H., et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996, 20:1161-1181.
37. Kimura K. Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach. Gastroenterology 1972, 63:584-592.
38. El-Zimaity H.M., Graham D.Y. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori intestinal metaplasia: role of the Sydney System. Hum Pathol 1999, 30:72-77.
39. Rugge M., Cassaro M., Pennelli G., et al. Atrophic gastritis: pathology and endoscopy in the reversibility assessment. Gut 2003, 52:1387-1388.
40. Isajevs S., Liepniece-Karele I., Janciauskas D., et al. The effect of incisura angularis biopsy sampling on the assessment of gastritis stage. Eur J Gastroenterol Hepatol 2014, 26:510-513.
41. Pizzi M., Saraggi D., Fassan M., et al. Secondary prevention of epidemic gastric cancer in the model of Helicobacter pylori-associated gastritis. Dig Dis 2014, 32:265-274.
42. Rugge M., Fassan M., Graham D.Y. Clinical guidelines: secondary prevention of gastric cancer. Nat Rev Gastroenterol Hepatol 2012, 9:128-129.
43. Rugge M., Capelle L.G., Cappellesso R., et al. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol 2013, 27:205-213.
44. Rugge M., Correa P., Dixon M.F., et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002, 16(7):1249-1259.
45. Rugge M., Genta R.M., OLGA Group Staging gastritis: an international proposal. Gastroenterology 2005, 129:1807-1808.
46. Rugge M., Genta R.M. Staging and grading of chronic gastritis. Hum Pathol 2005, 36:228-233.
47. Capelle L.G., de Vries A.C., Haringsma J., et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010, 71:1150-1158.
48. Talley N.J., Fock K.M., Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol 2008, 103:510-514.
49. de Vries A.C., Kuipers E.J., Rauws E.A. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn?. Am J Gastroenterol 2009, 104:1342-1345.
50. Rugge M., de Boni M., Pennelli G., et al. OLGA can guard the barn. Am J Gastroenterol 2009, 104:3101-3102.
51. Katanoda K., Saika K., Yamamoto S., et al. Projected cancer mortality among Japanese males under different smoking prevalence scenarios evidence for tobacco control goal setting. Jpn J Clin Oncol 2011, 41:483-489.
52. Bach P.B., Kattan M.W., Thornquist M.D., et al. Variations in lung cancer risk among smokers. Natl Cancer Inst 2003, 95:470-478.
53. Fassan M., Volinia S., Palatini J., et al. MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer 2011, 129:1661-1670.
54. Zabaleta J. MicroRNA: a bridge from H. pylori infection to gastritis and gastric cancer development. Front Genet 2012, 3:294.
55. Wang R., Wen H., Xu Y., et al. Circulating microRNAs as a novel class of diagnostic biomarkers in gastrointestinal tumors detection: meta-analysis based on 42 articles. PLoS One 2014, 9:e113401.
56. Fuccio L., Zagari R.M., Eusebi L.H., et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Ann Intern Med 2009, 151:121-128.
57. Yanaoka K., Oka M., Ohata H., et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer 2009, 125:2697-2703.
58. Wu C.Y., Kuo K.N., Wu M.S., et al. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009, 137:1641-1648.
59. Rugge M., Russo V.M., Guido M. Review article: what have we learnt from gastric biopsy?. Aliment Pharmacol Ther 2003, 17:68-74.
60. Rugge M., Cassaro M., Di Mario F., et al. Interdisciplinary Group on Gastric Epithelial Dysplasia (IGGED). The long term outcome of gastric non-invasive neoplasia. Gut 2003, 52:1111-1116.
61. Hojo M., Miwa H., Ohkusa T., et al. Alteration of histological gastritis after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2002, 16:1923-1932.
62. Fukase K., Kato M., Kikuchi S., et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008, 372:392-397.
63. Maehata Y., Nakamura S., Fujisawa K., et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc 2012, 75:39-46.
64. Yoon S.B., Park J.M., Lim C.H., et al. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter 2014, 19:243-248.
65. Graham D.Y., Uemura N. Natural history of gastric cancer after Helicobacter pylori eradication in Japan: after endoscopic resection, after treatment of the general population, and naturally. Helicobacter 2006, 11:139-143.
66. Lee C.W., Rickman B., Rogers A.B., et al. Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res 2008, 68:3540-3548.
67. Lin Y.S., Chen M.J., Shih S.C., et al. Management of Helicobacter pylori infection after gastric surgery. World J Gastroenterol 2014, 20:5274-5282.
68. Suh S., Nah J.C., Uhm M.S., et al. Changes in prevalence of Helicobacter pylori infection after subtotal gastrectomy. Hepatogastroenterology 2012, 59:646-648.
69. Cho S.J., Choi I.J., Kook M.C., et al. Randomised clinical trial: the effects of Helicobacter pylori eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer. Aliment Pharmacol Ther 2013, 38:477.